Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab

Digestive Diseases and Sciences

Volumn 60, Issue 9, 2015, Pages 2762-2770

  Steenholdt, Casper ^a   Brynskov, Jørn ^a   Thomsen, Ole Ø ^a   Munck, Lars K ^b   Fallingborg, Jan ^c   Christensen, Lisbet A ^d   Pedersen, Gitte ^e   Kjeldsen, Jens ^f   Jacobsen, Bent A ^c   Oxholm, Anne Sophie ^g   Kjellberg, Jakob ^h   Bendtzen, Klaus ⁱ   Ainsworth, Mark A ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b KØGE HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h KORA Danish Institute for Local and Regional Government Research ^*  (Denmark)

ⁱ Rigshospitalet   (Denmark)

Author keywords

Anti infliximab antibody; Crohn s disease; Inflammatory bowel disease; Infliximab; Loss of response; Maintenance therapy

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CROHN DISEASE; DRUG DOSE INTENSIFICATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TIME FACTOR; TREATMENT FAILURE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INFLIXIMAB; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PRECISION MEDICINE; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84939563221     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3581-4     Document Type: Article

References (21)

1. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–659.
2. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.
3. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355–366.
4. Dignass A, Van AG, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.
5. D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199–212.
6. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.
7. Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis. 2012;18:2026–2033.
8. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44:774–781.
9. Bendtzen K. Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy. 2012;4:1167–1179.
10. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919–927.
11. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol. 2011;46:310–318.
12. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med. 2013;15:201–211.
13. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–1139.
14. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:447–459.
15. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn’s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11:654–666.
16. Roblin X, Rinaudo M, Del TE, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1250–1256.
17. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20:1996–2003.
18. Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn’s disease. Lancet. 2000;356:1475–1479.
19. Steenholdt C, Bendtzen K, Brynskov J, et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn’s disease. J Crohns Colitis. 2015. Epub. 01/09/2015.
20. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672–1683.
21. Steenholdt C, Ainsworth MA. Authors’ response: importance of defining loss of response before therapeutic drug monitoring. Gut. (Epub ahead of print). doi:10.1136/gutjnl-2014-309044.